米拉贝隆对比安慰剂添加治疗接受坦索罗辛的前列腺增生男性膀胱过度活动症状的疗效与安全性:PLUS随机4期研究
PLUS研究为4期随机双盲试验,纳入676例接受坦索罗辛治疗的下尿路症状归因于良性前列腺增生且伴膀胱过度活动症状的男性,比较添加米拉贝隆25mg滴定至50mg与安慰剂的疗效与安全性。结果显示米拉贝隆在减少每日平均排尿次数方面优于安慰剂(-2.00 vs -1.62;校正差值-0.39;95%CI -0.76,-0.02),并在每次排尿量、每日尿急次数及总尿急频率评分上更优,但未改善国际前列腺症状总分;米拉贝隆组药物相关治疗中出现的不良事件及尿潴留率更高。
要点
- 米拉贝隆添加治疗可小幅减少每日排尿次数(校正差值-0.39次/日,95%CI -0.76,-0.02)。
- 米拉贝隆在每次排尿量、尿急次数及总尿急频率评分上优于安慰剂,但未改善IPSS总分。
- 米拉贝隆组药物相关不良事件及尿潴留率更高,需关注尿潴留风险。
核心结论
- 在接受坦索罗辛治疗的前列腺增生男性中,添加米拉贝隆可改善膀胱过度活动症状,但需注意尿潴留等不良事件。
研究设计与样本
- 4期随机双盲安慰剂对照研究,先经4周坦索罗辛0.4mg导入期,随后12周治疗期,初始米拉贝隆25mg或安慰剂添加,4周后滴定至50mg或安慰剂等效剂量。
- 共纳入676例男性,其中380例(56.2%)为65岁及以上。
主要发现
- 米拉贝隆组每日平均排尿次数变化为-2.00,安慰剂组为-1.62,校正差值-0.39(95%CI -0.76,-0.02)。
- 米拉贝隆在每次排尿量、每日尿急次数及总尿急频率评分上均优于安慰剂,但国际前列腺症状总分无统计学优势。
- 米拉贝隆组药物相关治疗中出现的不良事件率更高,尿潴留率也更高;安慰剂组总体治疗中出现的不良事件率更高。
- 排尿后残余尿量和最大尿流率结果无临床意义。
临床怎么用
- 对于坦索罗辛治疗后仍存在膀胱过度活动症状的前列腺增生男性,可考虑添加米拉贝隆以改善尿频、尿急及每次排尿量。
- 添加米拉贝隆时应监测尿潴留风险及药物相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PLUS investigated the efficacy and safety of mirabegron add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying lower urinary tract symptoms attributable to benign prostatic hyperplasia. MATERIALS AND METHODS: In this phase 4 study a 4-week 0.4 mg tamsulosin run-in period was followed by a 12-week, randomized, double-blind, treatment period in which patients initially received 25 mg mirabegron or placebo add-on therapy. At 4 weeks doses were titrated to 50 mg mirabegron or placebo equivalent. Efficacy end points were changes from baseline to end of treatment in mean number of micturitions per day (primary), mean volume voided per micturition, number of urgency episodes per day, total urgency and frequency score, and total International Prostate Symptom Score (secondary). Safety assessments included treatment emergent adverse events, and post-void residual volume, and maximum urinary flow measurements. RESULTS: Of the 676 men most were 65 years old or older (380, 56.2%). Tamsulosin plus mirabegron was statistically superior to tamsulosin plus placebo in reducing the mean number of micturitions per day (-2.00 vs -1.62; adjusted difference -0.39; 95% CI -0.76, -0.02). Statistically superior results were noted for tamsulosin plus mirabegron in mean volume voided per micturition, urgency episodes per day, and total urgency and frequency score (not International Prostate Symptom Score). Higher overall treatment emergent adverse event rates were observed with tamsulosin plus placebo, although higher rates of drug related treatment emergent adverse events were noted with tamsulosin plus mirabegron. Urinary retention rates were higher in the tamsulosin plus mirabegron group. Post-void residual volume and maximum urinary flow results were not clinically meaningful. CONCLUSIONS: The results of PLUS underscore the utility of mirabegron add-on therapy to treat men with overactive bladder symptoms receiving tamsulosin for benign prostatic hyperplasia.
引用
- Kaplan SA, Herschorn S, McVary KT, et al. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J Urol. 2020. PMID: 31895002. doi:10.1097/JU.0000000000000738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。